X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dr. Reddys with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs MYLAN (US) - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   MYLAN
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
MYLAN
Dec-18
DR. REDDYS LAB/
MYLAN
5-Yr Chart
Click to enlarge
High Rs2,8753,276-   
Low Rs1,8881,803-   
Sales per share (Unadj.) Rs930.21,507.4-  
Earnings per share (Unadj.) Rs117.440.9-  
Cash flow per share (Unadj.) Rs185.8323.2-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs844.41,630.7-  
Shares outstanding (eoy) m166.07514.50-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.61.7 152.0%   
Avg P/E ratio x20.362.0 32.7%  
P/CF ratio (eoy) x12.87.9 163.2%  
Price / Book Value ratio x2.81.6 181.1%  
Dividend payout %17.00-   
Avg Mkt Cap Rs m395,4961,306,551 30.3%   
No. of employees `00022.035.0 62.8%   
Total wages/salary Rs m33,5620-   
Avg. sales/employee Rs Th7,032.822,158.1 31.7%   
Avg. wages/employee Rs Th1,527.90-   
Avg. net profit/employee Rs Th887.7601.7 147.5%   
INCOME DATA
Net Sales Rs m154,482775,533 19.9%  
Other income Rs m3,3750-   
Total revenues Rs m157,857775,533 20.4%   
Gross profit Rs m31,782200,679 15.8%  
Depreciation Rs m11,348145,210 7.8%   
Interest Rs m88937,300 2.4%   
Profit before tax Rs m22,92018,168 126.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,858-2,890 -133.5%   
Profit after tax Rs m19,50021,059 92.6%  
Gross profit margin %20.625.9 79.5%  
Effective tax rate %16.8-15.9 -105.8%   
Net profit margin %12.62.7 464.9%  
BALANCE SHEET DATA
Current assets Rs m111,101433,057 25.7%   
Current liabilities Rs m58,973315,746 18.7%   
Net working cap to sales %33.715.1 223.1%  
Current ratio x1.91.4 137.4%  
Inventory Days Days7984 94.9%  
Debtors Days Days9493 100.9%  
Net fixed assets Rs m101,245150,441 67.3%   
Share capital Rs m830413 201.0%   
"Free" reserves Rs m139,4060-   
Net worth Rs m140,236838,985 16.7%   
Long term debt Rs m22,000905,534 2.4%   
Total assets Rs m224,6562,250,483 10.0%  
Interest coverage x26.81.5 1,801.0%   
Debt to equity ratio x0.21.1 14.5%  
Sales to assets ratio x0.70.3 199.5%   
Return on assets %9.12.6 350.0%  
Return on equity %13.92.5 554.0%  
Return on capital %14.93.2 470.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m69,5690-   
CASH FLOW
From Operations Rs m28,704161,156 17.8%  
From Investments Rs m-7,727-83,300 9.3%  
From Financial Activity Rs m-21,326-75,076 28.4%  
Net Cashflow Rs m-3141,335 -23.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.82 Rs / USD

Compare DR. REDDYS LAB With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare DR. REDDYS LAB With: BIOCON   WOCKHARDT  SHASUN PHARMA  ALKEM LABORATORIES  DIVIS LABORATORIES  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views On News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors (The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks (Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock (The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jul 19, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - AUROBINDO PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS